European stock markets began Wednesday's session on a positive note, with major indices rising as investors reacted to a fresh batch of corporate earnings reports.

Revenue at the unit, which houses AMD’s all-important artificial intelligence chips that are viewed as central to the company ...

The clouds may be lifting after a rough patch of results and a slump in coal prices, one set of analysts recently suggested, ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Sales within Diabetes and Obesity care increased by 16% in Danish kroner to DKK 145.4 billion (18% at CER), mainly driven by Obesity care growth of 56% in Danish kroner to DKK 38.8 billion (58% at CER ...

Shares of Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, fell in pre-market trading and on the ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...

For outsourcing and manufacturing professionals, 2024 may be remembered as the year capacity and partnerships took center ...

Danish pharmaceutical giant Novo Nordisk A/S (NVO) is facing serious headwinds. After enjoying a strong run fueled by demand for its obesity treatments, the obesity drug pioneer is now under pressure ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...